Arrhythmias & electrophysiology
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
Study context
- Population
- Atrial fibrillation (AF) patients without ischaemic stroke or intra-cranial haemorrhage (ICH) for years after AF diagnosis: previously without OAC (group 1, 'original non-OAC cohort') or continuously on warfarin (group 2, 'original warfarin cohort')group 1 n = 32,917
- Participants
- 54,803 patients
- Exposure
- NOAC vs warfarin vs no OAC
- Outcome
- Clinical outcomes
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
Ischaemic stroke, group 1 (original non-OAC cohort)
Each group vs Non-OACAdjusted hazard ratio (95% CI)P value
Warfarin
0.979(0.863–1.110)
P = 0.137NOAC
0.867(0.786–0.956)
P = 0.043Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| Composite outcomes, group 1 (original non-OAC cohort)NOACvs WarfarinIschaemic stroke or ICH | 0.927 (0.865–0.994) | P = 0.042 | |
| Composite outcomes, group 1 (original non-OAC cohort)NOACvs WarfarinIschaemic stroke or major bleeding | 0.912 (0.837–0.994) | P < 0.001 | |
| Ischaemic stroke, group 2 (original warfarin cohort)NOACvs WarfarinShifted to NOAC | 0.886 (0.790–0.993) | P = 0.002 | |
| 0.512Adjusted hazard ratio (log scale) |
Safety
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| Major bleeding, group 2 (original warfarin cohort)NOACvs WarfarinShifted to NOAC | 0.849 (0.756–0.953) | P < 0.001 | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study. Europace. Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →